Baseline characteristics

Cetuximab, Carboplatin, and Paclitaxel Followed by Radiation Therapy, With or Without Cisplatin, in Treating Patients With Metastatic Head and Neck Cancer · Source last updated 2013-04-05

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms

1. counts

   1. group Id

      BG000

      value

      47

   units

   Participants

groups

1. description

   Cetuximab beginning weekly dose 400 mg/m\^2 intravenous (IV), and 250 mg/m\^2 weeks 2-6; Weekly Carboplatin AUC 2 and Paclitaxel 135 mg/m\^2 for 6 courses.

   id

   BG000

   title

   Cetuximab + Carboplatin/Paclitaxel

measures

1. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            lower Limit

            21

            upper Limit

            78

            value

            53

   dispersion Type

   FULL_RANGE

   param Type

   MEDIAN

   title

   Age Continuous

   unit Of Measure

   years

2. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            value

            14

         title

         Female

      2. measurements

         1. group Id

            BG000

            value

            33

         title

         Male

   param Type

   COUNT_OF_PARTICIPANTS

   title

   Sex: Female, Male

   unit Of Measure

   Participants

3. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            value

            47

      title

      United States

   param Type

   NUMBER

   title

   Region of Enrollment

   unit Of Measure

   participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice